Race Oncology (ASX:RAC) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

RAC Overzicht aandelen

Race Oncology Limited, een biofarmaceutisch bedrijf in een klinische fase, richt zich op het voorzien in de onvervulde behoeften van kankerpatiënten aan schadelijke behandelingen.

Over het bedrijf

RAC fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 34.81% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen zinvolle omzet ( A$4M )

Race Oncology Limited Concurrenten

Aroa Biosurgery

ASX:ARX

AU$182.8m

Orthocell

ASX:OCC

AU$96.4m

Imugene

ASX:IMU

AU$357.0m

PYC Therapeutics

ASX:PYC

AU$793.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Race Oncology
Historische aandelenkoersen
Huidige aandelenkoers	AU$1.69
52 Week Hoogtepunt	AU$2.09
52 Week Laag	AU$0.64
Bèta	1.74
11 maand verandering	0.60%
3 maanden verandering	-2.87%
1 Jaar Verandering	98.82%
33 jaar verandering	-47.35%
5 jaar verandering	1,107.14%
Verandering sinds IPO	537.74%

Recent nieuws en updates

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Aug 26

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10

Recent updates

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07

Rendement voor aandeelhouders

	RAC	AU Biotechs	AU Markt
7D	-4.8%	1.5%	-0.7%
1Y	98.8%	18.3%	17.1%

Rendement versus industrie: RAC overtrof de Australian Biotechs industrie, die het afgelopen jaar een rendement 18.7 % opleverde.

Rendement versus markt: RAC overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 17.9 %.

Prijsvolatiliteit

Is RAC's price volatile compared to industry and market?
RAC volatility
RAC Average Weekly Movement	8.0%
Biotechs Industry Average Movement	10.3%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.7%

Stabiele aandelenkoers: RAC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van RAC is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	n/a	Daniel Tillett	www.raceoncology.com

Race Oncology Limited, een biofarmaceutisch bedrijf in een klinische fase, richt zich op het aanpakken van de onvervulde behoeften van kankerpatiënten aan schadelijke behandelingen. Het belangrijkste product van het bedrijf is bisantreen, een chemotherapeutisch middel op basis van kleine moleculen dat een klinische geschiedenis heeft met aangetoonde therapeutische voordelen bij volwassen en pediatrische patiënten. Het bedrijf is bezig met de ontwikkeling van geherformuleerd bisantreen (RC220) om tegemoet te komen aan de onvervulde behoeften van patiënten in verschillende oncologie-indicaties met een klinische focus op anthracycline-combinaties om cardioprotectie en verbeterde antikankeractiviteit te bieden in solide tumoren.

Race Oncology Limited Samenvatting

Hoe verhouden de winst en inkomsten van Race Oncology zich tot de beurswaarde?
RAC fundamentele statistieken
Marktkapitalisatie	AU$288.02m
Inkomsten(TTM)	-AU$13.82m
Inkomsten(TTM)	AU$4.00m

71.9x

P/S-verhouding

-20.8x

Koers/Winstverhouding

Is RAC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
RAC resultatenrekening (TTM)
Inkomsten	AU$4.00m
Kosten van inkomsten	AU$2.61m
Brutowinst	AU$1.39m
Overige uitgaven	AU$15.21m
Inkomsten	-AU$13.82m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.081
Brutomarge	34.72%
Nettowinstmarge	-345.18%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde RAC op de lange termijn?

Bekijk historische prestaties en vergelijking

RAC Overzicht aandelen

Beloningen

Risicoanalyse

Race Oncology Limited Concurrenten

ASX:ARX

AU$182.8m

ASX:OCC

AU$96.4m

ASX:IMU

AU$357.0m

ASX:PYC

AU$793.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

Recent updates

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel